Pfizer
Pfizer Studying Talzenna in Advanced Prostate Cancer Patients With DNA Damage Response Gene Defects
The Phase III trial will randomize metastatic castration-sensitive prostate cancer patients to Talzenna plus Xtandi or just Xtandi.
Keytruda, Hormone Therapy Combination Benefits Advanced Breast Cancer Subgroup in AACR Study
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement
The company is studying gedatolisib with palbociclib and endocrine therapy in patients with ER-positive, HER2-negative metastatic breast cancer.
Pyxis Oncology Raises $152M in Series B Financing
The company said it will use the proceeds to advance its portfolio of antibody-drug conjugates, which include PYX-201, PYX-202, and PYX-203.
Pfizer Grants Pyxis Oncology Licenses to Develop Two Antibody-Drug Conjugate Candidates
Pfizer will receive an undisclosed upfront payment from Pyxis for the license to the two drugs, as well as milestone payments and sales-based royalties.